Search

Psoriasis is a chronic, systemic, immune-mediated, inflammatory skin disease associated with significant comorbidities. Globally, there are an estimated 60 million people living with psoriasis (PLwP). There is a growing body of evidence on the role of diet in psoriasis management, and demand for dietary advice is high. However, there are no specific, evidence-based dietary guidelines. This scoping review summarises the literature on use and effectiveness of diet in the management of psoriasis to improve understanding of the evidence and assist PLwP and healthcare professionals (HCPs) to discuss diet. The findings were categorised into three themes: (1) dietary intakes of PLwP, (2) the perceived role of diet in psoriasis management and (3) dietary approaches to manage psoriasis symptoms. In cross-sectional studies PLwP were reported to have higher fat and lower fibre intakes compared with controls, and lower psoriasis severity was associated with higher fibre intake. However, research is limited. PLwP perceive diet to have an impact on symptoms and make dietary modifications which are often restrictive. Systematic reviews and RCTs found certain dietary approaches improved symptoms, but only in specific populations (e.g. PLwP with obesity and PLwP with coeliac disease), and evidence for supplement use is inconclusive. The grey literature provides limited guidance to PLwP; focusing on weight loss and associated comorbidities. Larger, controlled trials are required to determine dietary approaches for psoriasis management, especially in PLwP without obesity and non-coeliac PLwP. Further understanding of diet modification, information acquisition and experiences among PLwP will enhance holistic care for psoriasis management.

Keywords: biologic treatment; COVID-19; psoriasis; psoriasis management EN biologic treatment COVID-19 psoriasis psoriasis management 880 882 3 02/28/22 20220301 NES 220301 ACKNOWLEDGEMENT Open Access Funding provided by Universita degli Studi di Napoli Federico II within the CRUI-CARE Agreement. To the best of our knowledge, psoriasis treatment adherence, particularly biologics, was evaluated during the COVID-19 pandemic,7 confirming the safety and efficacy of these drugs during this period. COVID-19, psoriasis, biologic treatment, psoriasis management. [Extracted from the article]

Letter to the editor regarding article "Yalici-Armagan B, Tabak GH, Dogan-Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course. Herein, we describe our experience at the Dermatology Centre of the University of Naples Federico II, reporting that only 16/965 psoriasis patients (1.6%) stopped the biologic treatment during the early pandemic period (February 2020-June 2020).2 Among these, 13/16 (81.3%) voluntarily interrupted biologic therapy and the remaining (3/16, 18.8%) after seeking medical advice. Keywords: biologic treatment; COVID-19; psoriasis; psoriasis management EN biologic treatment COVID-19 psoriasis psoriasis management 4073 4075 3 12/02/21 20211201 NES 211201 CONFLICT OF INTEREST None. [Extracted from the article]

Background: Over the past years, with the availability of relatively well tolerated, very effective but expensive drugs, biologics, treatment of psoriasis has dramatically shifted from inpatient modalities to outpatient ones. Relatively little is known about true life practices regarding psoriasis treatment in our country. Aims: To assess the impact of introduction of conventional drugs and biological drugs on medical resource use of psoriasis patients. Study design: A retrospective chart review was performed. Methods: Patients with the diagnosis of psoriasis who were seen in the period between 2010 and 2015 were included in the study. Data including hospital resource use (inpatient, outpatient, day ward) and treatment modalities were collected. Results: The study population comprised 845 patients with 1053 different treatment modalities. There was not any significant difference between number of in-hospital days and frequency of hospitalization between biological drugs and cyclosporine. There was significant (p < .05) decline in the length of hospitalization after the year 2012 in biological treatment group. Conclusions: Treatment of MSP with classical drugs requires fairly similar medical resource expenditures as biologics. [ABSTRACT FROM AUTHOR]

Psoriasis is a chronic skin disorder that speeds up the life cycle of skin cells, typically on the surface of the skin. Additional skin cells form thick scales and red fixes which are awfully itchy and sometimes painful. Although there are many therapeutic systems available to get symptomatic relief, unfortunately replete cure for psoriasis is not yet reported. Moreover, poor treatment outcomes as well as high toxicity profile of drugs makes these therapies more inconvenient to treat psoriasis. In search of alternative and complementary therapy for this disease, the focus has been shifted to nutraceuticals, few of them were reported since ages. It includes vitamins, herbal extracts, phytochemicals and dietary supplements. In this review, the attempt has been made to highlight key nutraceuticals for better management of psoriasis. Supplementation of appropriate nutraceutical may improve the quality of patient's life and have positive impact on overall state of disease. [ABSTRACT FROM AUTHOR]

Background: Psoriasis is a complex and heterogeneous disease resulting from interactions between genetic, immunological, and environmental factors. To make the most optimal treatment decision, the dermatologist must therefore have a detailed overview of the patient’s history and lifestyle.Objectives: We sought to offer an overview of the various relevant aspects in clinical dermatological assessment of psoriasis patients, emphasizing the importance of a multidisciplinary and integrated clinical approach.Methods: We gathered information on psoriasis management and developed a tailored checklist covering all health-related aspects associated with psoriasis.Results: Demographics, personal and family history were elaborately described as well as drug history to discuss how they affect psoriasis management. Relevant patient information such as the vaccination status or cardiovascular profile were included in the checklist as well and treatment recommendations were adapted and updated in accordance with evidence-based literature. This checklist also emphasizes the importance of drug surveillance, proper follow-up and specialist referral, and why the dermatologist needs to address these health-related aspects when assessing psoriasis patients, going beyond optimal skin care.Conclusions: Our comprehensive overview can be used as a consultation checklist for good clinical practice in psoriasis patient management and aid in treatment decision. [ABSTRACT FROM PUBLISHER]

Psoriasis is a chronic skin condition that has a significant impact on quality of life, self-esteem and comorbidities. Management of this condition is complicated and heavily influenced by psychosocial and economic realities. Addressing psychosocial and treatment education issues can be facilitated by use of the National Psoriasis Foundation. Localized disease is generally treated with topical treatment for which good generic medications are available. Somewhat higher priced branded vehicles are helpful for enhancing patients' treatment adherence, and may help avoid the need for far more toxic and expensive systemic treatment. Patients with extensive disease are best managed with phototherapy as a first-line option, and there is room for improvement in how insurers promote the use of this approach. Biologic treatments continue to offer new, safer options for patients with severe disease, albeit at higher cost. This review addresses practical issues in psoriasis management that would be of interest to organizations that are involved in the delivery of care for patients with psoriasis, such as managed care pharmacists and pharmaceutical companies that develop products for psoriasis. [ABSTRACT FROM AUTHOR]

Objectives : Psoriasis is a chronic skin disease requiring a multidimensional approach, given its varying appearance, presence of comorbidities and complex treatment regimens. Psoriasis care is however often performed fragmented and, in case of flares, reactive with little integrated information on and for the patient. Literature suggests a multileveled approach of psoriasis, but the effects of its implementation have not yet been validated. The aim of this study is to analyze the impact of a multileveled psoriasis consultation format, named PsoPlus, which has been implemented since 2012 in the Department of Dermatology at Ghent University Hospital in Belgium. Methods : The patient population was divided into two groups: one following the regular consultation and one following the PsoPlus format. Demographic data, clinical outcome and treatment approach of psoriasis patients were compared. Results : Patients who opted for the specialized PsoPlus consultation were younger and had longer disease duration. Decision parameters such as disease severity and quality of life were reported more often in the PsoPlus group. In the latter, a higher rate of patients were started on systemic therapy compared to the regular consultation group, and reporting on adverse events was done more frequently. Conclusion : The implementation of a specialized consultation with comprehensive guidance facilitates documentation on disease-relevant parameters such as disease severity and quality of life. This format can be seen as a guidance for capturing data in a structured manner, with evidence showing that it significantly impacts treatment decision, treating not only psoriasis but the patient as a whole.